Eupraxia Pharmaceuticals Inc.
EPRXHealthcare|Biotechnology|CA
$6.89
+0.29 (+4.39%)
DCF Value
$1.44
Tangible Book / Share
$1.95
Cash / Share
$2.02
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05608681 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | Eosinophilic Esophagitis | P1P2 | Recruiting | 117 | RCT, Double-blind | EP-104GI |
| NCT04120402 Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee | Osteoarthritis, Knee | P2 | Completed | 318 | RCT, Double-blind | EP-104IAR 25 mg, Vehicle |
| NCT02609126 Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis | Osteoarthritis, Knee | P1 | Completed | 32 | RCT, Double-blind | EP-104IAR, Vehicle |